Information  X 
Enter a valid email address

Company Name matching 'MeiraGTx'

Date
Time Source
Company
Announcement
11 May 2021 1:00 pm GNW   MeiraGTx MeiraGTx Reports First Quarter 2021 Financial and Operational Results
05 May 2021 9:30 pm GNW   MeiraGTx MeiraGTx Announces Participation at Upcoming Investor Conferences
19 Apr 2021 9:30 pm GNW   MeiraGTx MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
11 Mar 2021 1:00 pm GNW   MeiraGTx MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
26 Jan 2021 1:30 pm GNW   MeiraGTx MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
16 Dec 2020 9:30 pm GNW   MeiraGTx MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
30 Nov 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
23 Nov 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
19 Nov 2020 12:00 pm GNW   MeiraGTx MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
18 Nov 2020 9:24 pm GNW   MeiraGTx MeiraGTx Announces Proposed Public Offering of Ordinary Shares
13 Nov 2020 10:55 pm GNW   MeiraGTx MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
10 Nov 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
05 Nov 2020 1:30 pm GNW   MeiraGTx MeiraGTx Reports Third Quarter 2020 Financial Results
03 Oct 2020 3:50 pm GNW   MeiraGTx MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)
28 Sep 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference
22 Sep 2020 1:30 pm GNW   MeiraGTx MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
06 Aug 2020 1:00 pm GNW   MeiraGTx MeiraGTx Reports Second Quarter 2020 Financial Results
05 Aug 2020 1:30 pm GNW   MeiraGTx MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
17 Jul 2020 12:30 pm GNW   MeiraGTx MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients  
26 May 2020 1:30 pm GNW   MeiraGTx MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders
07 May 2020 9:30 pm GNW   MeiraGTx MeiraGTx Reports First Quarter 2020 Financial Results
06 May 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
11 Mar 2020 9:00 pm GNW   MeiraGTx MeiraGTx Reports Full Year 2019 Financial Results
02 Mar 2020 1:30 pm GNW   MeiraGTx MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
24 Feb 2020 9:30 pm GNW   MeiraGTx MeiraGTx to Present at Upcoming Investor Conferences
05 Dec 2019 9:30 pm GNW   MeiraGTx MeiraGTx to Host Parkinson’s Disease R&D Day in New York
26 Nov 2019 9:30 pm GNW   MeiraGTx MeiraGTx to Present at Upcoming Healthcare Conferences
07 Nov 2019 1:00 pm GNW   MeiraGTx MeiraGTx Reports Third Quarter 2019 Financial Results
03 Oct 2019 9:45 pm GNW   MeiraGTx MeiraGTx to Present at Upcoming Scientific and Investor Conferences
10 Sep 2019 1:30 pm GNW   MeiraGTx MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences
08 Aug 2019 11:50 am GNW   MeiraGTx MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
07 Aug 2019 9:12 pm GNW   MeiraGTx MeiraGTx Announces Proposed Public Offering of Ordinary Shares
  1:00 pm GNW   MeiraGTx MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
14 May 2019 1:00 pm GNW   MeiraGTx MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
  12:30 pm GNW   MeiraGTx MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
10 May 2019 1:30 pm GNW   MeiraGTx MeiraGTx Appoints Nicole Seligman to Board of Directors
06 May 2019 9:30 pm GNW   MeiraGTx MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference
25 Apr 2019 9:30 pm GNW   MeiraGTx MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019
26 Mar 2019 8:05 pm GNW   MeiraGTx MeiraGTx Reports Full Year 2018 Financial Results
06 Mar 2019 9:30 pm GNW   MeiraGTx MeiraGTx to Present at the Barclays Global Healthcare Conference
27 Feb 2019 1:15 pm GNW   MeiraGTx MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
21 Feb 2019 9:30 pm GNW   MeiraGTx MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors
05 Feb 2019 1:30 pm GNW   MeiraGTx MeiraGTx to Present at the BIO CEO & Investor Conference
31 Jan 2019 11:30 am GNW   MeiraGTx MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
02 Jan 2019 1:30 pm GNW   MeiraGTx MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference
12 Dec 2018 1:30 pm GNW   MeiraGTx MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease
26 Jun 2018 1:00 pm GNW   MeiraGTx MeiraGTx Receives Positive Opinion for Orphan Drug Designation in the European Union for AAV-CNGA3 for the Treatment of Achromatopsia
12 Jun 2018 11:05 pm GNW   MeiraGTx MeiraGTx Announces Closing of Initial Public Offering


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t